D
Dorothee Nickles
Researcher at Genentech
Publications - 32
Citations - 7639
Dorothee Nickles is an academic researcher from Genentech. The author has contributed to research in topics: Atezolizumab & T cell. The author has an hindex of 17, co-authored 32 publications receiving 5113 citations. Previous affiliations of Dorothee Nickles include University of California, San Francisco & German Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg,Jean H. Hoffman-Censits,Thomas Powles,Michiel S. van der Heijden,Arjun Vasant Balar,Andrea Necchi,Nancy A. Dawson,Peter H. O'Donnell,Ani Balmanoukian,Yohann Loriot,Sandy Srinivas,Margitta Retz,Petros Grivas,Richard W. Joseph,Matthew D. Galsky,Mark D. Fleming,Daniel P. Petrylak,Jose Luis Perez-Gracia,Howard A. Burris,Daniel Castellano,Christina Canil,Joaquim Bellmunt,Dean F. Bajorin,Dorothee Nickles,Richard Bourgon,Garrett M. Frampton,Na Cui,Sanjeev Mariathasan,Oyewale O. Abidoye,Gregg Fine,Robert Dreicer +30 more
TL;DR: Treatment with atezolizumab resulted in a significantly improved RECIST v1.1 response rate, compared with a historical control overall response rate of 10%, and Exploratory analyses showed The Cancer Genome Atlas (TCGA) subtypes and mutation load to be independently predictive for response to atezolediazepine.
Journal ArticleDOI
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Sanjeev Mariathasan,Shannon J. Turley,Dorothee Nickles,Alessandra Castiglioni,Kobe C. Yuen,Yulei Wang,Edward E. Kadel,Hartmut Koeppen,Jillian L. Astarita,Rafael Cubas,Suchit Jhunjhunwala,Romain Banchereau,Yagai Yang,Yinghui Guan,Cecile Chalouni,James Ziai,Yasin Senbabaoglu,Stephen Santoro,Daniel Sheinson,Jeffrey Hung,Jennifer M. Giltnane,Andrew A. Pierce,Kathryn Mesh,Steve Lianoglou,Johannes Riegler,Richard A.D. Carano,Pontus Eriksson,Mattias Höglund,Loan Somarriba,Daniel L. Halligan,Michiel S. van der Heijden,Yohann Loriot,Jonathan E. Rosenberg,Lawrence Fong,Ira Mellman,Daniel S. Chen,Marjorie C. Green,Christina Louise Derleth,Gregg Fine,Priti S. Hegde,Richard Bourgon,Thomas Powles +41 more
TL;DR: Tumours from a large cohort of patients with metastatic urothelial cancer who were treated with an anti-PD-L1 agent were examined and major determinants of clinical outcome were identified and suggested that TGFβ shapes the tumour microenvironment to restrain anti-tumour immunity by restricting T-cell infiltration.
Journal ArticleDOI
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott,Mahrukh Huseni,Michael B. Atkins,Robert J. Motzer,Brian I. Rini,Bernard Escudier,Lawrence Fong,Richard W. Joseph,Sumanta K. Pal,James A. Reeves,Mario Sznol,John D. Hainsworth,W. Kimryn Rathmell,Walter M. Stadler,Thomas E. Hutson,Martin Gore,Alain Ravaud,Sergio Bracarda,Cristina Suarez,Riccardo Danielli,Viktor Gruenwald,Toni K. Choueiri,Dorothee Nickles,Suchit Jhunjhunwala,Elisabeth Piault-Louis,Alpa Thobhani,Jiaheng Qiu,Daniel S. Chen,Priti S. Hegde,Christina Schiff,Gregg Fine,Thomas Powles +31 more
TL;DR: Molecular profiles suggest that prediction of outcomes with anti-VEGF and immunotherapy may be possible and offer mechanistic insights into how blocking VEGF may overcome resistance to immune checkpoint blockade.
Journal ArticleDOI
Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients
Arumugam Palanichamy,Sarah Jahn,Dorothee Nickles,Mia Derstine,Aya Abounasr,Stephen L. Hauser,Sergio E. Baranzini,David Leppert,H.-Christian von Büdingen +8 more
TL;DR: It is shown that in MS patients, increased levels of CD3+CD20dim T cells are effectively depleted by RTX, and depletion of CD20-expressing T cells may also contribute to the therapeutic effect of RTX and other mAbs targeting CD20.
Journal ArticleDOI
Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment.
Huizhong Xiong,Stephanie Mittman,Ryan Rodriguez,Marina Moskalenko,Patricia Pacheco-Sanchez,Yagai Yang,Dorothee Nickles,Rafael Cubas +7 more
TL;DR: These results demonstrate that anti-PD-L1 treatment can favorably remodel the macrophage compartment in responsive tumor models toward a more proinflammatory phenotype, mainly through increased IFNγ levels and suggest that directly targeting these cells with reprogramming and depleting agents may further augment the breadth and depth of response to anti- PD- L1 treatment in less responsive or more macrophages-dense tumor microenvironments.